Dr. Andrew Mortlock is an Executive Vice-President and Head of Early Development and Translational Science at Astellas Pharma. He is responsible for driving robust quality data to enable earlier informed decision making to accelerate Astellas’ most promising science and increase the success rates of its projects. Before joining Astellas, Andrew was Vice President and Global Franchise Head at AstraZeneca’s Late Development Oncology Unit, with global responsibility for several Phase 3 development projects. In his previous roles, he oversaw AstraZeneca’s hematology portfolio, led the oncology combination strategy, worked as Product Team Leader in the Early Development group and was responsible for the global small molecule oncology portfolio through Phase 2. Andrew has also served as Chief Scientific Officer at Acerta Pharma. Andrew completed his BA in chemistry and subsequent PhD at the University of Oxford, UK. Following this, he completed his postdoctoral studies in synthetic organic chemistry at the University of California at Berkeley, CA, U.S.